Age-related Macular Degeneration and Low Vision Month 2026: Make vision change visible before it becomes a barrier to care, work, and independence

Make vision change visible across the enterprise

February is recognized as Low Vision Awareness Month by the National Eye Institute and as Age-related Macular Degeneration and Low Vision Month by Prevent Blindness. The observance gives health systems a practical reason to examine a problem that crosses traditional service lines. A person may first mention difficulty reading medication labels during a primary-care visit, fail a driving-related task in occupational health, struggle to use a patient portal, miss a retinal injection because transportation falls through, or stop cooking safely after central vision loss. Each signal may appear small inside one department. Together they reveal whether the organization has a functioning pathway.

Age-related macular degeneration, or AMD, affects central vision. Neovascular AMD can progress quickly and often requires repeated intravitreal treatment. Dry AMD may progress more slowly, but advanced disease can still disrupt reading, face recognition, navigation, and other daily activities. Low vision is not one diagnosis. It describes persistent visual difficulty that remains after ordinary medical, surgical, or refractive correction and interferes with function. The care response therefore cannot stop at diagnosis or visual acuity. It must include the work a person needs and wants to do.

A reliable executive strategy holds four responsibilities together. First, make meaningful vision change easier to recognize. Second, move patients to the right level of diagnostic and retinal care without avoidable delay. Third, protect continuity when treatment is frequent, expensive, or dependent on a caregiver. Fourth, offer rehabilitation when vision cannot be restored fully. Separating these responsibilities creates gaps. A screening program without referral ownership creates findings without care. A retinal service without access support creates treatment plans that patients cannot sustain. A rehabilitation service that receives late or inconsistent referrals leaves usable function unrealized.

Recent evidence supports this whole-path view. In a national primary-care imaging platform, 1,190,754 gradable bilateral examinations produced suspected pathology in 32% of examinations, including suspected AMD in 3%. The study shows that non-mydriatic imaging can surface non-diabetic findings at scale, but a screening signal is not a confirmed diagnosis and the population entered through a diabetic screening program.⁴ At the other end of the pathway, a 2026 analysis of the English macular-care route emphasized earlier presentation, better referral quality, realistic demand and capacity planning, digital tools, patient-centered care, and care closer to home.⁷ The operating challenge is to connect those ends.

Leaders also need to distinguish clinical measurements from lived function. A cross-sectional study of 262 people across several ophthalmic conditions found that patient-perceived visual change was strongly associated with vision-related quality of life and was not adequately explained by visual acuity alone.⁶ That does not make one questionnaire item a universal performance measure. It does show why organizations need a validated patient-reported outcome beside acuity, imaging, injections, and appointment counts.

Build recognition and referral into ordinary care

Many patients do not enter through an eye clinic. They may report distortion, a blurred central spot, difficulty reading, reduced contrast, poor adaptation to dim light, a fall, or a new dependence on another person. Frontline teams need simple language for eliciting those changes and a clear threshold for escalation. The goal is not to teach every clinician to diagnose AMD. The goal is to prevent a meaningful change from disappearing inside a visit focused on another condition.

A practical recognition standard asks what changed, when it changed, which eye is affected, whether distortion or a central gap is present, and what activity has become unsafe or impossible. Urgent symptoms need an urgent route. Longer-standing functional loss needs assessment too. A person who cannot read discharge instructions, distinguish medication bottles, use a glucose device, or navigate a hospital corridor may face immediate safety risks even when the underlying eye condition is stable.

Primary-care imaging can expand reach, but its value depends on image quality, interpreter capacity, referral rules, and follow-through. The national telemedicine study demonstrates scale and the ability to detect multiple pathologies in one platform.⁴ Executives should resist the tempting but weak conclusion that installing a camera completes a screening strategy. A camera can create demand faster than specialty capacity can absorb it. Before deployment, leaders should specify what counts as gradable, which findings require same-day, rapid, or routine evaluation, who communicates the result, how patients are reached, and how completion is confirmed.

Referral quality matters because vague referrals create rework and delay. The receiving service should know the symptom pattern, duration, laterality, relevant ocular history, current acuity if available, functional consequence, imaging status, communication need, transportation constraint, and reason for urgency. The sending team should know whether the referral was accepted, scheduled, completed, redirected, or closed with another plan. A queue is not a pathway. A pathway has a named owner and a recoverable exception process.

Imaging standards should also account for variation. A 2026 systematic review of age-related choroidal thickness found different rates across ethnic groups and emphasized that proposed thresholds still need prospective validation.⁵ That evidence argues against a single automated cutoff applied without context. Local governance should define acceptable devices, acquisition protocols, image review, escalation, and periodic bias testing across age, race, ethnicity, ocular characteristics, and comorbid conditions.

Protect continuity when treatment is demanding

Neovascular AMD care can require repeated injections, imaging, specialist visits, transportation, caregiver coordination, and financing decisions. A treatment plan may be clinically sound and operationally impossible. Leaders should therefore examine missed and delayed treatment as system signals. The review by Choi and colleagues organized barriers into seven unranked categories: travel, psychological barriers, financial and socioeconomic burden, treatment regimen, comorbidities, provider barriers, and system barriers.¹⁵ Those categories are useful for local diagnosis, but they do not show which cause is largest in a particular organization.

Treatment burden should be measured directly. In a 2026 real-world study of treatment-resistant nAMD, switching to faricimab produced anatomical improvement for many patients, yet visual acuity remained stable and average treatment intervals stayed under six weeks.¹ The study does not prove that faricimab cannot reduce burden in other patients. It does show that leaders should not equate a new therapy with fewer visits without examining the local schedule, patient selection, outcomes, and exceptions.

Affordability can alter clinical trajectories. Bellanda and colleagues studied patients whose loss of nonprofit copay support forced a switch from branded anti-VEGF therapy to bevacizumab. The cohort experienced worsening anatomy, shorter injection intervals, poor outcomes in 15.7% of eyes, and switchback in 16.9%.³ This small retrospective study cannot establish what will happen in every substitution. It provides a strong operational warning: when coverage changes, the system needs a clinical risk review, not only a financial transaction.

A continuity protocol should identify people at risk before the next scheduled visit. Useful triggers include a new prior authorization, copay assistance ending, a transportation cancellation, caregiver unavailability, repeated rescheduling, missed imaging, language mismatch, technology failure, or a change in living situation. The response should be proportionate. Some patients need a reminder. Others need financial navigation, transportation, a different appointment time, coordinated bilateral treatment, a caregiver conference, or rapid clinical reassessment.

Executives should monitor demand and capacity at the same time. If referral volume grows while retinal slots remain fixed, delay simply moves downstream. The 2026 pathway analysis recommends forecasting current and future demand, improving referral priority, using scalable digital tools, and locating care closer to home when safe.⁷ Capacity plans should include injection rooms, imaging, medication handling, pharmacy, nursing, authorization work, documentation, cleaning, emergency response, interpreters, and rehabilitation referrals. A single visit may touch all of them.

Make rehabilitation part of the standard route

Low-vision rehabilitation helps people use remaining vision and other strategies to complete meaningful tasks. It can include functional vision assessment, optical and electronic devices, contrast and lighting changes, eccentric viewing practice, occupational therapy, orientation and mobility, home-safety work, accessible technology, counseling, and connection to community services. It should not be treated as a consolation offered only after every medical option is exhausted. Rehabilitation can occur alongside retinal monitoring and treatment.

A single-center retrospective study of 94 patients referred to a low-vision unit found significant improvement in distance and near acuity with task-specific aids. AMD was the most common diagnosis, representing 27.6% of the cohort.¹² The study lacks a control group and does not prove identical benefit in every setting. Its practical message is clear: referral can connect people to measurable functional gains, and device selection should follow goals rather than a generic catalog.

Digital aids create opportunity and implementation risk. In a 2026 survey of 270 eye-care professionals in Jordan, 42.2% reported using or recommending electronic low-vision aids. High cost, limited training, weak institutional support, and low patient awareness were prominent barriers. Greater training exposure and institutional support were associated with adoption.¹⁴ Buying devices without training, technical support, accessible instruction, financing, and follow-up is unlikely to create durable use.

Home-based rehabilitation may extend reach, but evidence gates matter. A small randomized feasibility study combined clinic biofeedback with remotely monitored virtual-reality training for older adults with dry AMD. Data transmission was feasible and no participant met the cybersickness stopping rule, but recruitment fell short, only 11 people were analyzed for the primary outcome, completion in the VR arm was 75%, and group-level effectiveness was not established.⁹ An executive pilot should therefore measure accessibility, adoption, adverse effects, headset burden, technical failure, retention, task improvement, and durability before procurement expands.

Mental health belongs inside the pathway. A 2026 review of problem-solving therapy included five studies and found evidence of improved emotional well-being and perceived function among visually impaired adults. One included AMD study reported a 50% lower incidence of depressive disorders, although the overall evidence base was small and heterogeneous.¹¹ The correct operational response is not to promise a fixed effect. It is to screen for distress, isolation, and loss of confidence, then provide accessible support with follow-up.

Rehabilitation referral should be triggered by function, not only by a visual-acuity threshold. Ask whether the person can read medication instructions, see food and appliance controls, manage finances, use a telephone, participate in work, move safely indoors and outdoors, recognize faces, and access written or digital information. The care plan should document the patient’s priority tasks, devices or strategies tried, training completed, barriers encountered, and whether the improvement is durable in the real environment.

Use technology to extend judgment, not replace it

Retinal imaging, artificial intelligence, remote review, home monitoring, and electronic aids can increase reach or reduce manual work. They can also create false reassurance, inaccessible interfaces, new queues, privacy concerns, and unequal performance. Every technology proposal should begin with the problem it is meant to solve. “Use AI” is not an operating objective. “Reduce the time from a gradable high-risk image to accepted retinal evaluation without widening disparities” is testable.

A 2026 development study used a vision-transformer model to select prognostically relevant OCT and infrared images from clinical reports. The framework achieved 89% accuracy in image selection and improved downstream prognostic prediction by 3.1 percentage points relative to the comparison approach.¹⁰ These results show technical promise. They do not establish external validity, real-world workload reduction, fairness, or better patient outcomes. Before deployment, governance should require independent validation, documented failure modes, human review, version control, drift monitoring, auditability, and a safe process when the model and clinician disagree.

The same caution applies to emerging treatment. A 2026 preclinical study of targeted gene delivery for dry AMD reported reduced inflammatory and oxidative injury and preserved retinal architecture in laboratory and animal models.² The study does not establish that the approach is safe or effective in people. Public education should distinguish an active research pipeline from available care so that hope does not become misinformation or delayed use of proven services.

Technology accessibility must be tested with the intended users. Font scaling, contrast, voice output, tactile controls, simple navigation, large touch targets, low-bandwidth performance, caregiver permissions, and telephone alternatives are operational requirements. A portal message that the patient cannot read is not communication. A home device that cannot be positioned or tolerated is not access. A remote program without a live recovery route can increase abandonment.

Design for equity, independence, and total value

Visual impairment can magnify existing barriers. A patient with limited English proficiency may receive inaccessible written instructions. A person living alone may have no transportation after dilation. Someone with hearing loss may struggle in a rehabilitation session built around spoken instruction. A rural patient may face several hours of travel for a brief procedure. A caregiver may lose wages repeatedly. These are not peripheral social details. They shape whether a clinical plan can be completed.

Cost analysis should include more than the price of an encounter. A Bulgarian synthesis reported that much of the socioeconomic burden of AMD and diabetic macular edema came from quality-of-life, productivity, and welfare losses rather than direct medical care.⁸ The estimates are country specific and should not be imported as United States budget assumptions. They support a broader value frame that includes preserved independence, reduced caregiver burden, safer medication management, and continued participation.

A model-based Italian analysis of a miniature telescope intervention for selected patients with late-stage AMD estimated gains in quality-adjusted survival. The intervention was cost-effective from the payer perspective and became cost-saving only when societal blindness costs were included.¹³ The model depends on Italian costs, eligibility, assumptions, and structured postoperative rehabilitation. Leaders evaluating any high-cost technology should reproduce the analysis with local inputs and verify that the rehabilitation capacity assumed by the model actually exists.

Equity review must look at the entire funnel. Compare who is reached, who produces a gradable image, who receives a result, who gets an accepted referral, who completes the examination, who starts and continues treatment, who receives a rehabilitation offer, and who achieves a priority functional goal. A program can look equitable at the first step and become unequal through accumulation of small losses.

Patient and caregiver voices should shape the operating design. Ask where the path requires too many calls, where instructions become unreadable, which waiting environments are hard to navigate, how appointment timing affects transportation, and what happens when a device fails. Feedback should be accessible by telephone, large print, digital formats compatible with assistive technology, and supported conversation. The organization should report what changed because of that feedback.

Turn February into a 90-day reliability test

An observance can create attention, but attention is useful only when it changes an operating condition. A health system does not need to redesign every eye-care service in one month. It can choose one population, one pathway, and one measurable failure. Examples include urgent referrals that are not accepted within one business day, injection visits disrupted by authorization, patients with central vision loss who never receive a rehabilitation offer, or portal messages that are inaccessible to people with low vision.

The first 30 days should establish the current state. Map the pathway with patients, caregivers, primary care, optometry, retina, rehabilitation, pharmacy, navigation, informatics, and community partners. Define the numerator and denominator for each transition. Review a sample of completed and failed cases. Identify the point where responsibility becomes unclear. Do not start with a large technology purchase.

Days 31 through 60 should test a small countermeasure. Use one site, one referral source, or one patient group. Build an exception queue with a named owner. Add a functional question to the intake process. Create a same-day response for coverage disruption. Reserve rehabilitation appointments for direct handoff. Test accessible instructions with actual users. Track intended and unintended effects.

Days 61 through 90 should compare results with baseline and decide whether to adapt, expand, or stop. Review improvement by access-risk group. Verify that faster flow did not increase inappropriate referrals, staff burden, or patient confusion. Document the operating standard, training requirement, technology control, and ongoing review cadence. The output should be a repeatable care improvement, not an awareness report.

The leadership standard is completed function

Age-related Macular Degeneration and Low Vision Month should not end with impressions, clicks, or screening counts. The stronger question is whether a person with meaningful vision change reached the right evaluation, began appropriate care, sustained that care, received access support, and regained or preserved the ability to complete important tasks.

The evidence does not support one universal intervention. It supports a disciplined operating approach. Detect signals without calling them diagnoses. Close referrals rather than merely placing them. Separate anatomical response from functional benefit and treatment burden. Respond to affordability changes as clinical risks. Offer rehabilitation based on function. Pilot technology with accessibility and evidence gates. Measure the experience of the entire path.

When those practices become routine, the observance becomes more than a calendar entry. It becomes a leadership test of whether the organization can see the barriers that patients already experience and remove them before vision loss becomes isolation, unsafe care, or preventable dependence.